About the Company
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on HALOZYME THERAPEUTICS, INC.
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $73.71, a high estimate of $91.00, and a low estimate of $60.00. Surpassing the previous average ...
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C.
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a ...
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global ...
--Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE ® drug delivery ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.78 Consensus ...
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and ...
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX ...
SAN DIEGO, July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval ...
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth ...
Overview HALO Halozyme Therapeutics Inc $53.57 -0.52 % Halozyme Therapeutics, Inc. HALO saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec ...
GAMMA Investing LLC Increases Holdings in Halozyme Therapeutics, Inc ...
Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The company has a 50-day moving average price of $55.49 and a 200 day moving average price of $56.57.
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million ...
The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN DIEGO, Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics ...
Halozyme: Roche files for added Herceptin approval
Halozyme Therapeutics Inc. said Friday that its partner Roche filed for marketing approval of a new version of the breast cancer drug Herceptin that the companies have been developing.Roche asked ...
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ: HALO) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications ...
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global ...
DUBLIN and SAN DIEGO, Nov. 23, 2020/ PRNewswire/-- Horizon Therapeutics plc and Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement that gives Horizon ...
Similar Companies
Loading the latest forecasts...